Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modulation of antitumor immunity--immunobiologic approaches.

× No keyword cloud information.

46 in total

Review 1. Antitumor activity of Corynebacterium parvum.

Authors: L Milas; M T Scott
Journal: Adv Cancer Res Date: 1978 Impact factor: 6.242

2. Tumor immunity to murine plasma cell tumors. II. Essential role of T lymphocytes in immune response.

Authors: B T Rouse; M Röllinghoff; N L Warner
Journal: Eur J Immunol Date: 1973-04 Impact factor: 5.532

3. Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.

Authors: E Hawrylko; G B Mackaness
Journal: J Natl Cancer Inst Date: 1973-11 Impact factor: 13.506

4. Macrophages in syngeneic animal tumours.

Authors: R Evans
Journal: Transplantation Date: 1972-10 Impact factor: 4.939

5. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue.

Authors: J Vaage
Journal: Cancer Res Date: 1971-11 Impact factor: 12.701

Review 6. Tumor antigens.

Authors: G Klein
Journal: Annu Rev Microbiol Date: 1966 Impact factor: 15.500

7. Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodeoxyuridine.

Authors: S Silagi; D Beju; J Wrathall; E Deharven
Journal: Proc Natl Acad Sci U S A Date: 1972-11 Impact factor: 11.205

8. Partial purification of a serum factor that causes necrosis of tumors.

Authors: S Green; A Dobrjansky; E A Carswell; R L Kassel; L J Old; N Fiore; M K Schwartz
Journal: Proc Natl Acad Sci U S A Date: 1976-02 Impact factor: 11.205

9. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors: E S Dye; R J North
Journal: J Exp Med Date: 1981-10-01 Impact factor: 14.307

10. Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon.

Authors: M Goto; A Mitsuoka; M Sugiyama; M Kitano
Journal: J Exp Med Date: 1981-07-01 Impact factor: 14.307

7 in total

1. Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

Authors: F Esquivel; C E Taylor; P J Baker
Journal: Infect Immun Date: 1991-09 Impact factor: 3.441

2. Antimetastatic action of orally administered lysozyme in mice bearing Lewis lung carcinoma.

Authors: G Sava; L Perissin; S Zorzet
Journal: Clin Exp Metastasis Date: 1988 May-Jun Impact factor: 5.150

3. The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.

Authors: R J North
Journal: Cancer Immunol Immunother Date: 1984 Impact factor: 6.968

4. Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma.

Authors: G Sava; J Tomasic; I Hrsak
Journal: Cancer Immunol Immunother Date: 1984 Impact factor: 6.968

5. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors: R J North
Journal: Cancer Immunol Immunother Date: 1984 Impact factor: 6.968

6. Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.

Authors: N Bloksma; F M Hofhuis; J M Willers
Journal: Cancer Immunol Immunother Date: 1985 Impact factor: 6.968

7. The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression.

Authors: R J North
Journal: Cancer Immunol Immunother Date: 1984 Impact factor: 6.968

7 in total